Leerink Partners analyst Jason Gerberry bumped his price target on Outperform-rated Momenta Pharmaceuticals (NASDAQ: MNTA) to $26.00 (from $25.00) following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Goldman Sachs Downgrades Momenta Pharmaceuticals (MNTA) to NeutralAugust 6, 2015 6:59 AM Cowen Raises Price Target on Momenta Phama (MNTA) Following 2Q Results August 5, 2015 9:57 AM Momenta Phama (MNTA) Reports Q2 Loss Per Share of 4c August 4, 2015 8:17 AM Momenta Pharmaceuticals Reports Second Quarter 2015 Financial ResultsAugust 4, 2015 8:00 AM